Exoblanc | Regulatory Notice for UK & EU Clinics — Human-Derived Ingredients
Exoblanc is a Korean exosome skin booster line manufactured by Linkus Global, sold under names including Exoblanc, Exoblanc Pro, and Exoblanc COS PN+. It’s positioned as a professional-use injectable for skin regeneration, elasticity, and collagen synthesis, delivered via a two-component system where a “BlancHA” solution is combined with a “BlancPowder.”
Before this product can be listed for sale, its ingredient sourcing needs to be reviewed against UK and EU regulatory frameworks. According to the manufacturer’s own published formulation, the core BlancPowder component contains Exosome Human Stem Cell Conditioned Media and Human Amniotic Fluid Cell Conditioned Media Extract — both derived from human biological tissue. This places Exoblanc’s injectable formulation in a materially different regulatory category from the synthetic HA and PDRN-based products elsewhere on this site, which are CE-marked under EU MDR and MHRA-recognised in the UK.
Products derived from human tissue or cells are typically subject to specific tissue and cell regulations in the UK and EU, separate from the standard medical device framework — and aesthetic use of human-derived biological injectables is not routinely authorised in either market in the way HA fillers are. I can’t confirm CE marking or MHRA approval for this specific formulation, so I’m not going to present it with the same regulatory language used for your other products.
Exoblanc — an injectable exosome skin booster whose core formulation contains human stem cell and amniotic fluid-derived conditioned media. Regulatory review required before this product can be listed for sale on ProAestheticSupply.eu.
Buy Clinic Essentials
Buy Exoblanc
Buy Exoblanc
Buy Bundles
Buy Bundles
Buy Bundles
Buy Bundles
Buy Bundles
Buy Bundles
Buy Bundles
Buy Bundles
Buy Bundles
Important Regulatory Information About Exoblanc
Human-derived biological ingredients — stem cell conditioned media, amniotic fluid extract, placenta extract, and similar materials — occupy a distinct regulatory space from the synthetic hyaluronic acid, PDRN, and PLLA products that make up the rest of your catalogue. In the EU and UK, products derived from human tissue and cells generally fall under separate frameworks from the Medical Devices Regulation, and their use in cosmetic/aesthetic injectables is not commonly authorised the way CE-marked HA fillers are.
Why hasn’t this product received standard sales copy?
Because I can’t verify that Exoblanc’s human-derived injectable formulation carries CE marking or MHRA-recognised status for aesthetic use in the UK or EU. Writing “buy online” copy that implies the same regulatory standing as your other CE-marked products would misrepresent what’s actually confirmed about this one.
Are all Exoblanc products affected by this?
Not necessarily — the brand also sells topical Exoblanc skincare (serums, creams) and an Exoblanc COS PN+ vial line, where the exosome sourcing isn’t as clearly documented as the core injectable’s BlancPowder formulation. If you specifically want the topical skincare products covered, that’s a fair candidate for our existing Exosome Skincare category treatment — let me know and I can build that content separately.
What should happen before this product is listed?
This is a decision for your regulatory or compliance contact — specifically, confirming the exact sourcing and regulatory clearance of each Exoblanc SKU you’re considering stocking. Once that’s resolved, I’m glad to write the full content set matching the format of your other products.
Contact our customer support team for guidance on currently available, fully regulated alternatives within our exosomes range, such as ReversHA.